Author's posts
The Forbes Healthcare Summit 2018: The Draft Agenda
We’re two weeks away from the big event. On November 28 we’ll host the Forbes Healthcare Summit, a 24-hour meeting (time off for sleep) of the top executives from the pharmaceutical, insurance and hospital sectors.
At 24, Two Entrepreneurs Took On Cancer. At 32, They’re Worth Hundreds Of Millions
Nat Turner and Zach Weinberg built Flatiron Health into a $2 billion company to pursue an impossible dream—combating cancer with big data. They’ve not only made fast progress, they’ve also gotten rich trying. A 30 Under 30 cover story.
A $3 Billion Startup’s Shares Gain On Hopes For A Cancer Blood Test
Shares in Guardant Health, which makes blood tests that can be used to detect mutations in cancer tumors, have doubled from the $19 price set in the company’s October 4 initial public offering.
Amarin’s Fish Oil Derived Drug Shows Great Promise — With Big Caveats
Was it the drug, Vascepa, that prevented cardiac deaths? Or was part of the result due to a placebo that wasn’t? ““Is this a one-off chance finding, or is it a drug that is an amazing addition to our armamentarium?”
Amarin’s Fish Oil Derived Drug Shows Great Promise — With Big Caveats
Was it the drug, Vascepa, that prevented cardiac deaths? Or was part of the result due to a placebo that wasn’t? ““Is this a one-off chance finding, or is it a drug that is an amazing addition to our armamentarium?”
DNA Sequencing Giant Illumina Will Buy Pacific Biosciences For $1.2 Billion – Exclusive CEO Interview
Illumina, the dominant maker of DNA sequencing machines, has agreed to purchase smaller rival Pacific Biosciences for $8 a share, or $1.2 billion, in an effort to cement its ownership of cutting-edge genetic research.
Swiss Startup Aims To Help Paralyzed People Walk
A group of scientists associated with GTX Medical, a Swiss medical device firm, published new evidence yesterday that using electricity to stimulate the spinal cord can help paralyzed people regain some walking ability.
Milestone Moment: A Parkinson’s Drug Moves Forward With Help From Michael J.Fox
Today, at a medical conference being hosted by the Michael J. Fox Foundation, a biotechnology is presenting the first human data from a Parkinson’s drug that several of the world’s largest drug companies nearly abandoned.
In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%
“We’ve got to make sure those who need [Repatha] can get it,” says Robert Bradway, Amgen’s chairman and chief executive. “The losers are the patients who have gone to the pharmacy counter and have not been able to get the medicine they need.”
FDA Experts May Reconsider Diabetes Drug Safety Rules
Today and tomorrow, the FDA is convening a panel of experts to give it advice on what kind of studies it should require to determine whether diabetes drugs help the heart, or hurt it.
